Markets · Asia · HKEX

1093.HK CSPC Pharmaceutical Group

HK$9.29 0.00%

Asia ·

Log

Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.

0.00%

YTD

-5.40%

P/E

—

P/B

—

ROE

—

Div yield

—

Beta

0.21

Market cap

—

RSI (14)

Next earnings

—

Previous session

close of Oct 9, 2026 · EOD, no live order book

Open

HK$9.88

HK$9.29

VWAP (n/a)

—

Day high

HK$10.04

Day low

HK$9.24

Volume

91.8M

VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.

Latest headlines

CSPC’s SYS6051 Trial Approval Adds New Angle To Valuation Story

Yahoo Finance · Apr 22

Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint

Yahoo Finance · Apr 1

Big Pharma Is Pouring Billions Into China’s Biotechs

Yahoo Finance · Sep 14

The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight

Yahoo Finance · Jun 1

2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation

Yahoo Finance · Apr 22

How Regulatory Approval for CSPC Pharmaceutical’s First C5 siRNA Therapy (SEHK:1093) Has Changed Its Investment Story

Yahoo Finance · Nov 7

Headlines via Yahoo Finance · links open the source · not an endorsement.

Research & reports

TradingView ↗

Charts & analysis

Yahoo Finance ↗

Quote & news

External resources — availability and opinions are theirs, not ours.

This is reference data for your own analysis — not a recommendation to buy or sell 1093.HK. Try it in the Lab to size a position and see the risk.